Table 1: Summary of all 20 specimens of 9 NLPHL patients.

Case

Date

Specimen

Histopathology

FCI

CD57+ (%)

CD4+CD8+ (%)

1-A

1-B

03/08

05/08

Core

Excision

Atypical

NLPHL

Positive

Positive

27

30

33

14

2-A

2-B

06/03

05/08

Excision

Excision

NLPHL

RH

Positive

Negative

48

7

21

1

3-A

3-B

01/10

02/10

Core

Excision

Atypical

NLPHL

Positive

Positive

40

47

10

3

4-A

4-B

05/10

06/10

Core

Core

NLPHL

NLPHL

Positive

Positive

25

25

20

21

5-A

5-B

06/08

12/11

Excision

Excision

NLPHL

RH

Positive

Negative

19

4

12

2

6-A

6-B

02/07

11/12

Excision

Excision

NLPHL

NLPHL

Positive

Positive

24

13

21

9

7-A

7-B

04/12

06/12

Excision

Core

NLPHL

Atypical

Positive

Positive

15

13

19

6

8-A

8-B

8-C

06/07

10/07

01/11

Excision

Excision

Excision

RH/PTGC

RH/PTGC

NLPHL

Positive

Positive

Positive

13

15

19

27

23

22

9-A

9-B

9-C

03/03

04/08

09/09

Excision

Excision

Excision

NLPHL

RH

RH/PTGC

Positive

Positive

Positive

22

6

9

1

6

8

FCI: Flow Cytometric Immunophenotyping; NLPHL: Nodular Lymphocyte-Predominant Hodgkin Lymphoma; RH: Reactive Hyperplasia, RH/PTGC: Reactive Hyperplasia with Progressive Transformation of Germinal Centers.